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Abstract
Introduction Higher flavonoid intakes are beneficially associated with pulmonary function parameters;
however, their association with chronic obstructive pulmonary disease (COPD) is unknown. This study
aimed to examine associations between intakes of 1) total flavonoids, 2) flavonoid subclasses and 3) major
flavonoid compounds with incident COPD in participants from the Danish Diet, Cancer and Health study.
Methods This prospective cohort included 55 413 men and women without COPD, aged 50–65 years at
recruitment. Habitual flavonoid intakes at baseline were estimated from a food frequency questionnaire
using Phenol-Explorer. Danish nationwide registers were used to identify incident cases of COPD.
Associations were modelled using restricted cubic splines within Cox proportional hazards models.
Results During 23 years of follow-up, 5557 participants were diagnosed with COPD. Of these, 4013 were
current smokers, 1062 were former smokers and 482 were never-smokers. After multivariable adjustments,
participants with the highest total flavonoid intakes had a 20% lower risk of COPD than those with the
lowest intakes (quintile 5 versus quintile 1: HR 0.80, 95% CI 0.74–0.87); a 6–22% lower risk was
observed for each flavonoid subclass. The inverse association between total flavonoid intake and COPD
was present in both men and women but only in current smokers (HR 0.77, 95% CI 0.70–0.84) and
former smokers (HR 0.82, 95% CI 0.69–0.97), not never-smokers. Furthermore, higher flavonoid intakes
appeared to lessen, but not negate, the higher risk of COPD associated with smoking intensity.
Conclusion Dietary flavonoids may be important for partially mitigating the risk of smoking-related
COPD. However, smoking cessation should remain the highest priority.

Introduction
Chronic obstructive pulmonary disease (COPD) is a common lung condition characterised by persistent
respiratory symptoms and irreversible airflow limitations due to an abnormal inflammatory response of the
lungs, usually caused by significant exposure to noxious gases or particles [1, 2]. While smoking is the
most common cause of COPD, other modifiable risk factors include air pollution; occupational exposure to
dust, vapours and fumes; and respiratory infections in early life [3]. Non-modifiable risk factors include
https://doi.org/10.1183/13993003.02604-2021
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age and genetic predisposition [4]. Given the high prevalence and burden of COPD worldwide, and that
there is currently no cure [5], prevention strategies should be prioritised.
There is emerging evidence that diet has an impact on lung function and may play a protective role against
COPD [6–8], likely through the modulation of inflammation and oxidative stress pathways that are
implicated in the development of this chronic disease [9]. In a prospective cohort study of Swedish men, a
strong inverse association between total fruit and vegetable consumption and COPD was observed in
current and former smokers but not in never-smokers [10]. Fruit and vegetables, as well as tea, cocoa and
other plant-based foods and beverages, are dietary sources of flavonoids, which are bioactive compounds
that reduce oxidative stress and systematic inflammation [11]. Flavonoids are a class of polyphenols, and
can be further categorised into subclasses based on their chemical structure. Although epidemiological
studies investigating the association between flavonoid intakes specifically and COPD are missing, there is
some evidence that flavonoid intakes are favourably associated with pulmonary function parameters [12, 13]
and less age-related decline in lung function [14].
The primary aim of this study was to investigate the associations between intakes of 1) total flavonoids,
2) flavonoid subclasses and 3) key flavonoid compounds within respective subclasses with incident COPD
in the Danish Diet, Cancer and Health cohort. In our previous work, a consistent finding was that
associations between flavonoid intake and a range of chronic diseases (including cardiovascular disease,
dementia and diabetes [15, 16]) were stronger in current and former smokers. Given the importance of
smoking as a risk factor for COPD, the purported antioxidant and anti-inflammatory properties of
flavonoids, and that there is evidence of sex-related differences in COPD risk and outcomes [17],
secondary aims were to explore interactions between flavonoid intakes and risk factors for COPD, namely
sex and smoking.

Methods
Study population
The present study was conducted using data collected from participants of the Danish Diet, Cancer and
Health study. A detailed description of the original study has been published previously [18]. In brief,
57 053 participants were recruited from the cities of Copenhagen and Aarhus in Denmark between 1993
and 1997. Upon enrolment, 56 468 of these participants completed a food frequency questionnaire (FFQ)
and had not been diagnosed with cancer. Data collected were cross-linked to the following nationwide
registers, using the unique and permanent civil registration number assigned to all Danish residents: the
Civil Registration System, the Integrated Database for Labor Market Research and the Danish National
Patient Register. The latter register [19] holds information on all hospital admissions and visits to
outpatient clinics and urgent care centres in Denmark since 1978. It includes one primary diagnosis and
one or more secondary diagnoses defined by the International Classification of Diseases (ICD) (8th
revision (ICD-8) until 1993 and 10th revision (ICD-10) from 1994 to present). In the present study,
participants were excluded if they had a diagnosis of COPD, unspecified chronic bronchitis or emphysema
prior to enrolment into the Danish Diet, Cancer and Health study (n=479; ICD-8: 491.00–492.09, ICD-10:
J42–J44), if they had reported improbable energy intakes (n=202; <2092 kJ per day (<500 kcal per day)
and >20 920 kJ per day (>5000 kcal per day)) or if they had missing or extreme values for covariates
(n=374; supplementary figure E1).
This study was approved by the Danish Data Protection Agency (ref no. 2012–58-0004 I-Suite nr: 6357,
VD-2018-117).

Exposures
Primary exposures of interest in the present study were total flavonoid intake (calculated by summing
intakes of each of the 219 flavonoid compounds) and intakes of flavonoid subclasses and individual
flavonoid compounds, with mean intakes >5 mg per day at baseline. A detailed description of how
flavonoid intakes were estimated from the FFQ using the Phenol-Explorer database [20] has been
published previously [15]. In brief, flavonoid estimates (mg per 100 g fresh food weight) for each food and
beverage in the FFQ (n=174) were derived from the Phenol-Explorer database taking into consideration
food processing using retention factors. These were then multiplied by intakes of respective foods and
beverages (g per day). In a post hoc investigative analysis, smoking pack-years (lifetime average number of
cigarettes smoked multiplied by the number of years smoked divided by 20) was modelled as the exposure
of interest.
https://doi.org/10.1183/13993003.02604-2021
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Study outcomes
The primary outcome was a first-time hospitalisation or outpatient visit with a primary or secondary
diagnosis of COPD (ICD-10: J44), unspecified chronic bronchitis (ICD-10: J42) or emphysema (ICD-10: J43).
The ICD-10 code J44 has previously been validated in the Danish National Patient Register and has a
positive predictive value of 92% (95% CI 91–93%) [21]. Because patients with COPD may have been
coded as having unspecified chronic bronchitis (ICD-10: J42) or emphysema (ICD-10: J43), these were
also included. A first-time diagnosis of COPD is the only validated method to identify COPD in Danish
registers; hereinafter this will be referred to as incident COPD. Most cases were identified by ICD-10
codes DJ449 (∼69%), DJ441 (∼12%) and DJ429 (∼8%).
Covariates
A description of the covariates used is given in the supplementary material and supplementary table E1.
Statistical analysis
Multivariable Cox proportional hazards models were used to investigate relationships between self-reported
flavonoid intake and incident COPD. Each participants’ time-to-event was calculated from the date of
enrolment into the Danish Diet, Cancer and Health study up until the date of a first-time diagnosis of
COPD, death, emigration from Denmark or the end of follow-up (August 2017), whichever came first. Cox
proportional hazards assumptions were tested by plotting Schoenfeld residuals, with no violation found. To
allow the association between all continuous covariates, including the exposures of interest, and outcome
to be non-linear, these variables were modelled with restricted cubic splines using the “rms” R package
with the rcs() function [22] in R (www.r-project.org). Quintiles (Q1–5) of each flavonoid exposure variable
were generated, and the median value of each quintile was calculated. Hazard ratios, obtained from the
Cox proportional hazards models described above, are relative to the median flavonoid intake in Q1
(reference value); these were plotted against the exposure variable, with 95% confidence interval bands
provided. In addition, hazard ratios and 95% confidence intervals were calculated from the fitted models,
comparing the median of each quintile to the reference value of the median in Q1, and tabulated. For
simpler visualisation, figures only include individuals with intakes ⩽3 SD above the mean. Three models of
adjustment were used: 1) minimally adjusted: age (years) and sex; 1b) multivariable-adjusted: age, sex,
body mass index (BMI), smoking status (current/former/never), smoking pack-years, physical activity (total
daily metabolic equivalent), pure alcohol intake (g per day), education (⩽7 years/8–10 years/⩾11 years)
and socioeconomic status (income); 2) multivariable-adjusted including potential dietary confounders: all
variables in Model 1b plus energy intake (kJ per day) and intakes (g per day) of fish, red meat, processed
meat, whole grains, refined grains, polyunsaturated fatty acids, monounsaturated fatty acids and saturated
fatty acids. Confounders were selected based on a priori knowledge [23–25].
A secondary aim was to investigate interactions with established risk factors for COPD [3] for which data
had been collected at baseline (specifically, smoking status and sex). First, analyses were stratified by sex
and smoking status to examine the consistency of the associations. Because there is potential for residual
confounding by smoking intensity, smoking pack-years was included as a covariate in the model when
stratifying by smoking status. Interaction on the multiplicative scale was assessed by likelihood ratio tests
of Cox proportional hazards models with and without the interaction terms. Second, standard logistic
regression models were used to obtain the 20-year absolute risk estimates of a healthcare visit for COPD.
These analyses used a binary outcome designating the occurrence of a COPD healthcare visit during the
first 20 years of follow-up. Unless indicated by the relevant stratification variable, these estimates are for
the “average” smoking cohort participant, i.e. a smoker, aged 56 years, with a BMI of 25.5 kg·m−2, a total
daily metabolic equivalent score of 56, a mean household income of 394 701–570 930 DKK per year and
an alcohol intake of 13 g per day. In a post hoc investigative analysis, we explored whether flavonoid
intake modified the association between smoking intensity (represented by pack-years) and COPD, by
plotting the predicted risk of COPD after 20 years of follow-up against pack-years, separately for men and
women in the highest and lowest flavonoid intake quintiles. For the aforementioned analysis, smoking
pack-years was entered in the model as a restricted cubic spline. Finally, to avoid the potential for
preclinical COPD leading to reverse causation, as a sensitivity analysis we omitted all cases that occurred
within the first 5 years of follow-up. All analyses were undertaken using STATA/IC 14.2 (StataCorp LLC)
and R statistics (www.r-project.org).
Results
In this population of 55 413 Danish residents with a median age of 56 years, 5557 incident cases of COPD
were identified during a maximum of 23 years of follow-up (median (IQR) follow-up: 21 years
(19–22 years)). Furthermore, 11 195 participants died without a prior hospital diagnosis of COPD and 276
(∼0.5%) were lost to follow-up.
https://doi.org/10.1183/13993003.02604-2021
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Baseline characteristics
Overall, the cohort reported a daily median (IQR) habitual flavonoid intake of 496 mg (287–805 mg).
Participants with higher total flavonoid intakes tended to be female and were more likely to be
non-smokers, have a lower BMI, exercise more and have a higher education and income. Those consuming
more flavonoids also ate, on average, more fish, whole grains, fruits and vegetables, and less red and
processed meat (table 1).
Associations of total and flavonoid subclass intakes with incident COPD
The inverse association between total flavonoid intake and incident COPD was non-linear
( pnon−linearity<0.001); the steepness of the slope decreased as flavonoid intakes increased (figure 1).
Compared to participants in Q1, participants in Q5 had a 20% lower risk of COPD (HR 0.80, 95% CI
0.74–0.87) after multivariable adjustments (Model 1b, table 2). Non-linear associations were also observed
for all flavonoid subclasses (pnon-linearity<0.001 for all, figure 1). Comparing high (Q4 or Q5) to low (Q1)
intakes, the risk of COPD was up to 18% lower for flavonols, 14% lower for flavanol monomers, 22%
lower for flavanol oligo+polymers, 12% lower for anthocyanins, 9% lower for flavanones and 15% lower
for flavones, after multivariable adjustments (Model 1b, table 2). Significant associations were apparent for
total flavonoid intakes (Q5 versus Q1: HR 0.85, 95% CI 0.78–0.92) and intakes of all flavonoid subclasses
when potential dietary confounders were included as predictors in the model (Model 2, table 2).
Associations between major flavonoid compound intakes and incident COPD
Non-linear associations with incident COPD were observed for intakes of all major flavonoid compounds
( pnon-linearity<0.001 for all, figure 2). Clear plateaus in the association were seen for intakes of kaempferol,
quercetin, epicatechin, hesperidin and apigenin. Associations appeared to be more linear for intakes of
malvidin and both proanthocyanidin dimers and trimers, and somewhat “u-shaped” for intakes of cyanidin
and delphinidin. The lowest hazard ratios observed were for participants with the highest intakes of
malvidin (Q5 versus Q1: HR 0.63, 95% CI 0.57–0.70; Model 1b; supplementary table E2).
Association between total flavonoid intake and incident COPD stratified by sex and smoking
Of the 5557 participants who were diagnosed with COPD during follow-up, 2605 were male and 2952
were female. The association between total flavonoid intake and incident COPD was present in both men
and women although the shapes of the associations differed; the association for women was initially
steeper, plateauing at a total flavonoid intake of ∼500 mg per day (pnon-linearity=0.013), while the association
for men was more linear (pnon-linearity=0.506, pinteraction<0.001, figure 3). On an absolute scale, women had a
higher risk of COPD than men irrespective of their smoking status or flavonoid intake (table 3).
Of the 5557 COPD events, 4013 were in current smokers, 1062 were in former smokers, and 482 were in
never-smokers. While a clear inverse association between total flavonoid intake and incident COPD was
present in current/former smokers (termed ever-smokers), there was no inverse association in those who
had never smoked ( pinteraction=0.017, figure 3). Current and former smokers with the highest total flavonoid
intakes had a 23% and 18% lower risk of COPD, respectively (current smokers Q5 versus Q1: HR 0.77,
95% CI 0.70–0.84; former smokers Q5 versus Q1: HR 0.82, 95% CI 0.69–0.97) after multivariable
adjustments (Model 1b, supplementary tables E3 and E4). Hazard ratios for other flavonoid subclasses and
compounds among current and former smokers only are presented in supplementary tables E3–E6. On an
absolute scale, current and former smokers had a substantially higher risk of COPD than non-smokers
irrespective of their flavonoid intake, although current smokers with a low flavonoid intake were at the
highest risk (table 3). For participants who were current smokers at baseline, the difference in the 20-year
predicted risk of COPD between a participant in the highest versus the lowest flavonoid intake quintile was
5.21% for men and 6.20% for women (table 3). Furthermore, for both men and women, flavonoid intakes
appeared to modify the association between smoking intensity ( pack-years) and predicted risk of COPD at
20 years in that participants with the highest flavonoid intakes (Q5) had a lower predicted risk of COPD
than their low flavonoid-consuming (Q1) counterparts (figure 4).
Sensitivity analysis
Excluding events within the first 5 years of follow-up did not materially alter the observed associations
(supplementary table E7).
Discussion
In this 23-year prospective cohort study of 55 413 Danish residents, we observed that baseline intakes of
each flavonoid subclass, and all major flavonoid compounds investigated, were non-linearly inversely
associated with incident COPD. The association between total flavonoid intake and incident COPD was
only present in current and former smokers, who accounted for 91% of the COPD events observed. In the
https://doi.org/10.1183/13993003.02604-2021
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TABLE 1 Baseline characteristics of study population
Total
population

Subjects, n
Total flavonoid intake (mg per day)
Sex (male)
Age (years)
BMI (kg·m−2)
MET score
Smoking status
Never
Former
Current
Education
⩽7 years
8–10 years
⩾11 years
Mean household income
(DKK per year)
⩽394 700
394 701–570 930
570 931–758 297
> 758 297
Hypertensive
Hypercholesterolemic
Comorbidities
Diabetes
Ischaemic heart disease
Ischaemic stroke
CKD
Medication use
Insulin treated
Antihypertensive
Statin
HRT
Never
Current
Former
NSAID
Aspirin
Dietary characteristics
Energy (kcal)
Total fish intake (g per day)
Red meat intake (g per day)
Processed meat intake (g per day)
Refined grain intake (g per day)
Wholegrain intake (g per day)
Dietary fibre intake (g per day)
Saturated FA (g per day)
Polyunsaturated FA (g per day)
Monounsaturated FA (g per day)
Fruit intake (g per day)
Vegetable intake (g per day)
Alcohol intake (g per day)

Total flavonoid intake quintiles
Q1

Q2

Q3

Q4

Q5

55 413
496 (287–805)

11 083
174 (127–213)

11 083
321 (287–357)

11 082
496 (442–549)

11 083
727 (660–805)

26 352 (47.6)
56 (52–60)
25.5 (23.3–28.2)
56.5 (37.0–84.8)

6410 (57.8)
56 (52–60)
26.1 (23.8–28.9)
51.0 (32.3–78.0)

5669 (51.2)
56 (52–60)
25.9 (23.6–28.5)
55.5 (36.3–84.0)

5279 (47.6)
56 (52–60)
25.6 (23.3–28.3)
57.4 (38.0–85.0)

4923 (44.4)
56 (52–60)
25.3 (23.2–27.9)
58.5 (38.5–87.0)

11 082
1203 (1025–
1436)
4071 (36.7)
55 (52–60)
24.9 (22.7–27.4)
60.0 (39.8–88.5)

19 629 (35.4)
15 862 (28.6)
19 922 (36.0)

2737 (24.7)
2659 (24.0)
5692 (51.3)

3743 (33.8)
2969 (26.8)
4364 (39.4)

3982 (35.9)
3203 (28.9)
3895 (35.2)

4442 (40.1)
3527 (31.8)
3112 (28.1)

4725 (42.6)
3504 (31.6)
2859 (25.8)

18 143 (32.7)
25 558 (46.1)
11 684 (21.1)

5051 (45.6)
4847 (43.7)
1184 (10.7)

4191 (37.8)
5211 (47.0)
1670 (15.1)

3539 (31.9)
5298 (47.8)
2239 (20.2)

2972 (26.8)
5250 (47.4)
2852 (25.7)

2390 (21.6)
4952 (44.7)
3739 (33.7)

13 634 (24.6)
13 842 (25.0)
13 953 (25.2)
13 984 (25.2)
9288 (16.8)
4138 (7.5)

3270 (29.5)
3238 (29.2)
2909 (26.2)
1671 (15.1)
1839 (16.6)
902 (8.1)

2694 (24.3)
2959 (26.7)
3011 (27.2)
2412 (21.8)
1891 (17.1)
820 (7.4)

2658 (24.0)
2683 (24.2)
2870 (25.9)
2869 (25.9)
1888 (17.0)
845 (7.6)

2535 (22.9)
2565 (23.1)
2598 (23.4)
3383 (30.5)
1846 (16.7)
848 (7.7)

2477 (22.3)
2397 (21.6)
2565 (23.1)
3649 (32.9)
1824 (16.5)
723 (6.5)

1158 (2.1)
2116 (3.8)
769 (1.4)
200 (0.4)

275 (2.5)
561 (5.1)
214 (1.9)
42 (0.4)

215 (1.9)
403 (3.6)
145 (1.3)
33 (0.3)

249 (2.2)
424 (3.8)
145 (1.3)
43 (0.4)

211 (1.9)
383 (3.5)
130 (1.2)
42 (0.4)

208 (1.9)
345 (3.1)
135 (1.2)
40 (0.4)

683 (1.2)
6797 (12.3)
1085 (2.0)

158 (1.4)
1337 (12.1)
265 (2.4)

121 (1.1)
1398 (12.6)
214 (1.9)

152 (1.4)
1379 (12.4)
222 (2.0)

129 (1.2)
1348 (12.2)
213 (1.9)

123 (1.1)
1335 (12.0)
171 (1.5)

15 810 (54.4)
8742 (30.1)
4478 (15.4)
17 934 (32.6)
6983 (12.6)

2584 (55.2)
1282 (27.4)
803 (17.2)
3493 (31.7)
1362 (12.3)

3014 (55.7)
1551 (28.7)
838 (15.5)
3493 (31.8)
1345 (12.1)

3241 (55.9)
1682 (29.0)
871 (15.0)
3594 (32.6)
1420 (12.8)

3233 (52.5)
1996 (32.4)
923 (15.0)
3589 (32.5)
1370 (12.4)

3738 (53.3)
2231 (31.8)
1043 (14.9)
3765 (34.2)
1486 (13.4)

2271 (1878–
2717)
38 (25–55)
78 (56–107)
25 (14–40)
46 (29–72)
128 (86–175)
20 (16–25)
31 (24–39)
13 (10–17)
27 (21–35)
171 (95–281)
162 (105–231)
13 (6–31)

2060 (1680–
2484)
33 (22–49)
80 (58–108)
28 (17–45)
45 (27–80)
116 (72–165)
16 (13–20)
29 (23–37)
12 (9–16)
26 (20–34)
87 (44–141)
114 (71–170)
11 (3–23)

2214 (1844–
2629)
38 (25–54)
81 (59–110)
26 (15–42)
46 (29–73)
123 (84–171)
19 (16–23)
31 (24–39)
13 (10–17)
27 (21–35)
161 (98–238)
150 (100–212)
13 (6–25)

2330 (1944–
2768)
40 (27–57)
80 (58–110)
25 (14–40)
47 (30–72)
126 (86–173)
21 (17–25)
32 (24–40)
14 (10–18)
28 (22–35)
193 (114–301)
168 (114–235)
15 (6–34)

2375 (1988–
2824)
41 (28–59)
78 (57–107)
23 (14–38)
46 (30–70)
135 (97–181)
22 (18–27)
32 (25–41)
14 (11–18)
28 (22–35)
224 (140–360)
185 (127–254)
14 (7–32)

2373 (1976–
2842)
40 (27–57)
72 (52–99)
20 (11–34)
45 (30–68)
144 (103–193)
23 (19–29)
32 (24–41)
14 (10–18)
27 (21–34)
240 (141–390)
196 (135–272)
13 (6–32)

Data expressed as median (IQR) or n (%), unless otherwise stated. Q: quintile; BMI: body mass index; MET: metabolic equivalent; DKK: Danish
Krone; CKD: chronic kidney disease; HRT: hormone replacement therapy; NSAID: nonsteroidal anti-inflammatory drug; FA: fatty acids.
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FIGURE 1 Cubic spline curves describing the association between total flavonoid and flavonoid subclass
intakes and chronic obstructive pulmonary disease (COPD)-related healthcare visits in participants of the
Danish Diet, Cancer and Health cohort (n=55 413). Hazard ratios and 95% confidence intervals are based on
Cox proportional hazards models adjusted for age, sex, body mass index, smoking status, smoking pack-years,
physical activity, education, social economic status (income) and alcohol intake (Model 1b) and compare the
specific level of flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake
quintile.

present study, the “average” cohort participant who was both a current smoker and a low flavonoid
consumer at baseline had between an ∼6% (women) and ∼5% (men) higher risk of COPD than their
high-flavonoid-consuming counterparts. Furthermore, a high flavonoid intake appeared to lessen, but not
negate, the risk of COPD associated with higher smoking intensity.
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FIGURE 2 Cubic spline curves describing the association between major flavonoid compound intakes and
chronic obstructive pulmonary disease (COPD)-related healthcare visits in participants of the Danish Diet,
Cancer and Health cohort (n=55 413). Hazard ratios and 95% confidence intervals are based on Cox
proportional hazards models adjusted for age, sex, body mass index, smoking status, smoking pack-years,
physical activity, social economic status (income) and alcohol intake (Model 1b) and are comparing the specific
level of flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake quintile.

In 2001, the first study to examine the association between dietary flavonoid intake and lung function
reported a beneficial inverse association between intakes of catechins, flavonols and flavones (the only
flavonoid subclasses for which food content data were available at the time) and forced expiratory volume in
1 s (FEV1) [26]. Despite these findings, there have been very few studies since. A longitudinal analysis of
participants of the Veterans Affairs Normative Aging Study [14] demonstrated inverse associations between
anthocyanin intake and age-related decline in lung function, a risk factor for COPD [27], in current, former
and never-smokers. More recently, two cross-sectional studies reported protective associations between
various flavonoid subclasses and pulmonary function parameters [12, 13]. To our knowledge, the present
study is the first to investigate associations between dietary flavonoid intakes and incident COPD. Our
findings of clear inverse associations for all flavonoid subclasses, after multivariable adjustments for
demographic, lifestyle and dietary confounders, highlights the need for further research in this important, yet
sparsely investigated, area. Furthermore, that we see evidence of a plateau in the association, even in
high-risk groups, points to optimal flavonoid intakes that are achievable with diet alone.
In the present study, the association between flavonoid intake and COPD was only present in current and
former smokers and the absolute risk of COPD in both current and former smokers was lower for those
with the highest flavonoids intakes; this aligns with the hypothesis that flavonoids may work to counteract,
https://doi.org/10.1183/13993003.02604-2021
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TABLE 2 Hazard ratios for chronic obstructive pulmonary disease by quintiles of flavonoid intake
Flavonoid intake quintiles

Subjects, n
Total flavonoids
Events, n
Intake (mg per day)#
HR (95% CI)
Model 1
Model 1b
Model 2
Flavonols
Events (n)
Intake (mg per day)#
HR (95% CI)
Model 1
Model 1b
Model 2
Flavanol monomers
Events, n
Intake (mg per day)#
HR (95% CI)
Model 1
Model 1b
Model 2
Flavanol oligo+polymers
Events, n
Intake (mg per day)#
HR (95% CI)
Model 1
Model 1b
Model 2
Anthocyanins
Events, n
Intake (mg per day)#
HR (95% CI)
Model 1
Model 1b
Model 2
Flavanones
Events, n
Intake (mg per day)#
HR (95% CI)
Model 1
Model 1b
Model 2
Flavones
Events, n
Intake (mg per day)#
HR (95% CI)
Model 1
Model 1b
Model 2

Q1

Q2

Q3

Q4

Q5

11 083

11 083

11 082

11 083

11 082

1621
174 (6–251)

1222
321 (251–395)

1085
496 (395–602)

861
727 (602–910)

768
1203 (910–3552)

ref.
ref.
ref.

0.71 (0.68–0.75)
0.94 (0.90–0.99)
0.96 (0.91–1.01)

0.55 (0.52–0.59)
0.89 (0.84–0.95)
0.92 (0.86–0.98)

0.48 (0.45–0.51)
0.85 (0.79–0.91)
0.88 (0.82–0.95)

0.43 (0.40–0.46)
0.80 (0.74–0.87)
0.85 (0.78–0.92)

1665
15 (0–21)

1286
26 (21–32)

989
39 (32–50)

869
66 (50–83)

748
116 (83–251)

ref.
ref.
ref.

0.73 (0.70–0.76)
0.93 (0.89–0.97)
0.95 (0.91–1.00)

0.57 (0.53–0.60)
0.88 (0.83–0.94)
0.92 (0.86–0.98)

0.45 (0.42–0.49)
0.85 (0.79–0.91)
0.89 (0.83–0.96)

0.42 (0.39–0.45)
0.82 (0.76–0.89)
0.88 (0.81–0.95)

1636
14 (0–21)

1217
30 (21–46)

1086
67 (46–115)

861
261 (115–282)

757
474 (282–916)

ref.
ref.
ref.

0.81 (0.79–0.84)
0.96 (0.93–0.99)
0.97 (0.94–1.00)

0.59 (0.55–0.63)
0.90 (0.84–0.97)
0.94 (0.87–1.01)

0.45 (0.42–0.49)
0.87 (0.81–0.94)
0.92 (0.85–0.99)

0.45 (0.41–0.48)
0.86 (0.80–0.93)
0.91 (0.84–0.98)

1642
92 (1–136)

1230
179 (136–217)

1016
256 (217–303)

898
360 (303–434)

771
537 (434–2254)

ref.
ref.
ref.

0.67 (0.64–0.70)
0.93 (0.88–0.98)
0.94 (0.90–0.99)

0.54 (0.51–0.57)
0.87 (0.83–0.93)
0.90 (0.84–0.95)

0.48 (0.45–0.51)
0.82 (0.77–0.88)
0.85 (0.79–0.91)

0.44 (0.41–0.47)
0.78 (0.72–0.84)
0.81 (0.74–0.87)

1525
5 (0–10)

998
13 (10–17)

904
20 (17–24)

1035
36 (24–53)

1095
70 (53–397)

ref.
ref.
ref.

0.64 (0.61–0.67)
0.91 (0.86–0.95)
0.91 (0.86–0.96)

0.53 (0.50–0.57)
0.87 (0.81–0.93)
0.88 (0.82–0.95)

0.59 (0.55–0.63)
0.88 (0.83–0.95)
0.90 (0.84–0.97)

0.72 (0.67–0.77)
0.91 (0.84–0.98)
0.93 (0.86–1.01)

1462
3 (0–6)

1075
9 (6–13)

996
17 (13–26)

1005
32 (26–49)

1019
70 (49–564)

ref.
ref.
ref.

0.78 (0.75–0.82)
0.94 (0.90–0.99)
0.94 (0.90–0.99)

0.65 (0.60–0.70)
0.91 (0.84–0.97)
0.91 (0.84–0.97)

0.64 (0.60–0.68)
0.91 (0.86–0.97)
0.91 (0.85–0.97)

0.69 (0.64–0.74)
0.94 (0.88–1.01)
0.94 (0.87–1.01)

1501
2 (0–3)

1179
4 (3–4)

944
5 (4–6)

922
7 (6–9)

1011
11 (9–51)

ref.
ref.
ref.

0.70 (0.67–0.74)
0.91 (0.87–0.96)
0.92 (0.87–0.97)

0.59 (0.55–0.62)
0.87 (0.82–0.92)
0.88 (0.82–0.93)

0.55 (0.52–0.59)
0.85 (0.8–0.90)
0.86 (0.8–0.92)

0.58 (0.54–0.63)
0.87 (0.81–0.93)
0.88 (0.81–0.95)

Hazard ratios (95% confidence intervals) for chronic obstructive pulmonary disease during 23 years of follow-up obtained from restricted cubic
splines based on Cox proportional hazards models. Model 1 adjusted for age and sex; Model 1b adjusted for age, sex, body mass index, smoking
status, smoking pack-years, physical activity, alcohol intake, education and socioeconomic status (income); Model 2 adjusted for all covariates in
Model 1b plus energy intake and fish, red meat, processed meat, whole grains, refined grains, polyunsaturated fatty acids, monounsaturated fatty
acids and saturated fatty acids. Q: quintile. #: median (range).
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Stratified by baseline smoking status
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3
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Total flavonoid intake (mg per day)
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FIGURE 3 Multivariable-adjusted association between total flavonoid intake and chronic obstructive pulmonary
disease (COPD)-related healthcare visits stratified by baseline smoking status and sex. Hazard ratios and 95%
confidence intervals are based on Cox proportional hazards models and are comparing the specific level of
flavonoid intake (horizontal axis) to the median intake for participants in the lowest intake quintile (174 mg per
day). All analyses were standardised for age, sex, body mass index, smoking status, smoking pack-years,
physical activity, social economic status (income), education and alcohol intake (Model 1b).

in part, the increases in systemic inflammation and oxidative stress induced by smoking [28] that give rise to
COPD [29]. This hypothesis is supported by findings from our post hoc exploratory analysis that the risk of
COPD associated with a higher number of smoking pack-years is lower in participants who consume more
flavonoid-rich foods. There is a substantial overlap between pathways involved in cigarette smoke-induced
inflammation and oxidative stress [29, 30] and those identified as being modulated by flavonoids [31]. That
flavonoids may protect against COPD by inhibiting oxidative stress and inflammation through these
signalling pathways has been demonstrated in a cigarette smoke-induced COPD mouse model supplemented
with flavonoids extracted from loquat leaves [32] and a cigarette smoke-induced COPD rat model in which
the animals were supplemented with the flavonoid fisetin [33]. While human intervention studies are lacking,
a 2-week supplementation with flavonoid-rich grape juice decreased smoking-induced inflammation in a
randomised controlled trial conducted in healthy smokers [34]. In the present study, on the relative scale, the
association between total flavonoid intake and COPD was apparent in both men and women, although the
shapes of the associations appeared to differ. The reasons underpinning this are difficult to determine given
that, due to the complexity of interacting physiological, behavioural and/or genetic factors, it is not yet fully
understood why women have a higher risk of COPD than men [35].
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TABLE 3 20-year predicted risk of chronic obstructive pulmonary disease
Total flavonoid intake

Male
Never-smoker
Former smoker
Current smoker
Female
Never-smoker
Former smoker
Current smoker

Risk difference (%)

Q1 risk (95% CI)

Q5 risk (95% CI)

2.35 (2.07–2.66)
6.26 (5.68–6.89)
18.53 (17.31–19.82)

1.60 (1.39–1.84)
4.32 (3.85–4.84)
13.32 (12.10–14.65)

0.75
1.94
5.21

3.06 (2.71–3.45)
8.06 (7.31–8.87)
22.99 (21.53–24.52)

2.09 (1.84–2.37)
5.59 (5.02–6.22)
16.79 (15.41–18.26)

0.97
2.47
6.20

The 20-year predicted risks (%) of chronic obstructive pulmonary disease calculated from logistic regression
models. Unless indicated by the stratification variable, these estimates are for a smoking participant aged
56 years with a body mass index of 25.5 kg·m−2, a total daily metabolic equivalent score of 56, a mean
household income of 394 701–570 930 DKK per year and an alcohol intake of 13 g per day.

Men
20-year predcited risk of COPD (%)

50

Low flavonoid intake
High flavonoid intake
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20
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0
0
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20

30
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FIGURE 4 The 20-year predicted risks (%) and 95% confidence intervals of chronic obstructive pulmonary
disease (COPD) by smoking pack-years for high (quintile 5) versus low (quintile 1) total flavonoid intakes,
presented separately for men and women. The predicted risks are calculated from logistic regression models and
are for a participant aged 56 years, with a body mass index of 25.5 kg·m−2, a total daily metabolic equivalent
score of 56, a mean household income of 394 701–570 930 DKK per year and an alcohol intake of 13 g per day.
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The 20-year absolute risk of COPD for the “average” cohort participant who was both a current smoker
and a low flavonoid consumer was ~6% (for women) or ~5% (for men) higher than for their
high-flavonoid-consuming counterparts. This risk difference was less for former smokers (∼2% each for men
and women) although their risk of COPD was approximately one third that of current smokers. Reducing
COPD cases by ∼2% in former smokers and ∼5–6% in current smokers would have a huge public health
impact, which leads to the question of whether dietary modifications should be of higher priority in current
and former smokers. However, irrespective of flavonoid intake, both current and former smokers had a
substantially higher risk of COPD (∼8- and ∼3-fold higher, respectively) than non-smokers, reminding us
that targeting smoking cessation is, and must continue to be, the top priority for reducing COPD risk.
The current study has numerous strengths, including a large adult population followed for 23 years with a
relatively large number of events, allowing us to examine associations in subpopulations, and a negligible
loss to follow-up, allowing for the estimation of absolute risks. Although our hypothesis and subsequent
findings are supported by mechanistic evidence, this study is observational in nature and thus we cannot
confirm causality. We also acknowledge that persons in this cohort with a higher flavonoid intake tended
to have healthier diet and lifestyle and we cannot rule out the possibility of residual or unmeasured
confounding. Furthermore, there may have been misclassification in the exposures because diet was
self-reported using an FFQ and may have changed over time. Likewise, smoking status and intensity were
only captured at baseline and thus changes during follow-up could not be accounted for. In the Danish
National Patient Register, COPD diagnoses are underreported and diagnosis in primary care only would
not have been captured, which may have led to lower estimation of COPD events during follow-up [21].
However, these exposure and outcome misclassifications would likely bias examined associations towards
the null. Moreover, clinical data on COPD severity such as spirometry data and symptom severity of
COPD were not available.
We show that current and former smokers consuming a flavonoid-rich diet have a lower risk of COPD than
those with low flavonoid intakes. While the findings of this study suggest an importance of dietary
flavonoids in partially mitigating the risk of COPD in people who smoke, both current and former smokers
remained at a substantially higher risk of COPD than non-smokers, indicating that dietary modifications
should be secondary to smoking cessation.
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